DUBLIN–(BUSINESS WIRE)–The “Stem
Cell Therapies for Cardiovascular and Metabolic Disorders, 2019-2030”
report has been added to ResearchAndMarkets.com’s
offering.
The Stem Cell Therapies for Cardiovascular & Metabolic Disorders,
2019-2030 report features an extensive study of the current market
landscape and the future potential of stem cell therapies in treating
the aforementioned clinical conditions.
The study includes all stem cell therapies that are being developed for
the treatment of cardiovascular and metabolic disorders. In addition, we
have provided a list of stem cell therapies being developed for stroke,
a condition associated with vasculature in the brain.
Amongst other elements, the report features the following:
-
A detailed assessment of the current market landscape of stem cell
therapies with respect to target therapeutic area (cardiovascular and
metabolic), phase of development (approved, phase III, phase II, phase
I and preclinical / discovery), target disease indications
(Cardiovascular: heart failure, myocardial infarction, critical limb
ischemia, angina, peripheral arterial / vascular diseases, myocardial
ischemia, myocardial fibrosis, cardiomyopathy and coronary
microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis
type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic
leukodystrophy), source of cells (autologous and allogenic), type of
stem cells (adult multipotent, adult pluripotent, embryonic
multipotent, embryonic pluripotent and others), stem cell lineage
(bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle,
Wharton’s jelly, umbilical cord, placenta, dental pulp, cord blood and
pancreas), and route of administration (intramyocardial,
intramuscular, intravenous, intracoronary, subcutaneous implantation
and surgical implantation). -
An analysis highlighting the key unmet needs across cardiovascular and
metabolic disorders, featuring insights generated from social media
posts, recent scientific publications, patient blogs and the views of
contemporary key opinion leaders as expressed on online platforms. -
An overview of the focus areas of therapy developers, including an
assessment of the existing opportunity for stem cell therapies across
diverse therapeutic indications. -
An insightful company competitiveness analysis featuring a
three-dimensional bubble representation, highlighting the key players
in this domain on the basis of the strength of their respective
product portfolios, taking into consideration the number of therapies
under development, phase of development of these therapies, number of
disease indications being targeted and geographical distribution of
affiliated clinical trials. -
An analysis of the partnerships that have been established in the
domain in the period 2012-2018, covering R&D collaborations, licensing
agreements, mergers and acquisitions, product development and/or
commercialization agreements, manufacturing agreements, clinical trial
agreements, process development agreements, and other relevant deals. -
An analysis of the investments made at various stages of development
in companies that are focused in this area, including seed financing,
venture capital financing, capital raised from IPOs / secondary
offerings, debt financing and grants. -
An analysis of contemporary peer-reviewed scientific research articles
published during the period 2013-2018, highlighting the key focus
areas of the ongoing research activity, in terms of therapeutic area,
target disease indication, and source of cells. -
Comprehensive profiles of approved and late-stage clinical products;
each profile features an overview of the therapy, its mechanism of
action, history of development, current development status, key
clinical trial results, details on recommended dose, price and
manufacturing process (wherever available). -
One of the key objectives of the report was to understand the primary
growth drivers and estimate the future size of the market. Based on
parameters, such as target consumer segments, likely adoption rates
and expected pricing, we have provided an informed estimate of the
likely evolution of the market in the short to mid-term and long term,
for the period 2019-2030. -
The report includes information on (potential) sales-based revenues
generated by stem cell therapies that are currently marketed or are in
late stages of development for the treatment of cardiovascular and
metabolic disorders. Additionally, it presents details on the likely
distribution of the current and forecasted opportunity across [A]
target therapeutic areas (cardiovascular and metabolic), [B] target
disease indications (myocardial ischemia, heart failure, critical limb
ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other
cardiovascular and metabolic disorders ), [C] type of stem cells
(adult multipotent, adult pluripotent and embryonic multipotent), [D]
source of cells (autologous and allogenic), [E] stem cell lineage
(bone marrow, peripheral blood and others), [F] route of
administration (intramyocardial, intracoronary, intramuscular,
intravenous and surgical implantation) and [G] key geographical
regions (North America, Europe and Asia Pacific). To account for the
uncertainties associated with the development of novel therapy
products and to add robustness to our model, we have provided three
forecast scenarios, portraying the conservative, base and optimistic
tracks of the market’s evolution.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Unmet Need Analysis
6. Key Therapeutic Areas
7. Company Competitiveness Analysis
8. Partnerships And Collaborations
9. Funding And Investment Analysis
10. Publication Analysis
11. Stem Cell Therapies For Cardiovascular Disorders: Therapy Profiles
12. Stem Cell Therapies For Metabolic Disorders: Therapy Profiles
13. Market Forecast
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/r/9oaflt
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Stem
Cells